Andre Basbaum

Andre has over 22 years of business development, financing, licensing, and commercial expertise in the biotechnology industry. He has been involved in the formation and growth of several biotech companies in human health and plant science. Prior to Siolta Therapeutics, Andre served as the vice president of global business development and US operations at ACEA Therapeutics, a biotechnology company operating in the US, China, and Hong Kong. Prior to ACEA, Andre held management positions of increasing responsibility at Trovagene (now Cardiff Oncology), SGB, Yulex, VentiRx (acquired by Celgene), Anadys (IPO and acquired by Roche), Valent International, and Pfizer, leading the execution of multiple collaborations and licensing transactions with academia and pharmaceutical companies valued at over $500M. Andre obtained his Global Executive M.B.A. from IE Business School, Spain, and a BA in business administration from Pontificia Universidade Católica de Sao Paulo, Brazil.